Non-Coding RNA Assays Market Size

  • Report ID: 3730
  • Published Date: Jul 24, 2024
  • Report Format: PDF, PPT

Non-Coding RNA Assays Market Size

Non-Coding RNA Assays Market size was valued at USD 269.08 Million in 2023 and is projected to cross USD 1.56 Billion by the end of 2036, expanding at more than 14.5% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of non-coding rna assays is estimated at USD 304.19 Million. The growth of the market can be attributed to the increasing investment in medical research. Further, the need for assays that can accurately detect and quantify ncRNAs is being driven by the increase in research activities that use these molecules, which is also expected to add to the market growth. As of 2018, total U.S. spending on medical and health research and development (R&D) increased by over 6%.

In addition to these, factors that are believed to fuel the market growth of non-coding RNA assays include the surging government initiatives to promote life science research projects. For instance, in life sciences, research initiatives, non-coding RNA (ncRNA) tests have grown in importance, as they provide information on the roles and control mechanisms of ncRNAs in the cell. Additionally, the growing advancements in technology have enabled the development of more sensitive and accurate ncRNA detection assays, which are predicted to present the potential for market expansion over the projected period.


Non-Coding Rna Assays Market Overview
Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 3730
  • Published Date: Jul 24, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of non-coding rna assays is estimated at USD 304.19 Million.

The non-coding rna assays market size was valued at USD 269.08 Million in 2023 and is projected to cross USD 1.56 Billion by the end of 2036, expanding at more than 14.5% CAGR during the forecast period i.e., between 2024-2036. Growing prevalence of chronic diseases, and rising geriatric population are the major factors driving the market growth.

North America is anticipated to grow with the highest CAGR through 2036, attributed to availability of a large number of biotechnology and pharmaceutical companies.

Thermo Fisher Scientific Company, Springer Nature Limited, Applied Microarrays Inc., C D Genomics, RELX Group, MilliporeSigma, QIAGEN, Agilent Technologies, Inc., Danaher Corporation, Eppendorf SE
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample